the highest hormone activity, ORD is generally regarded as an activating and IRD as an inactivating pathway.
Sulfation has a dramatic effect on these processes (2) .
The IRD of T4 sulfate (T4S) and T3S by rat ID-I is about 200 and 40 times faster, respectively, than the IRD of the non-sulfated compounds, whereas the ORD of T4S is completely blocked. Also, human ID-I catalyzes the IRD of T3S much more efficiently than the IRDofT3 (16) .
Because it strongly facilitates the IRD of T4 and T3 by ID-I, sulfation appears to be a primary step in a pathway mediating the rapid, irreversible degradation of thyroid hormone when ID-I activity is normal. However, the lifetime of these conjugates is markedly prolonged if their deiodination by ID-I is prevented (8, 17) , resulting in their accumulation in plasma and a subsequent increase in their biliary excretion (7, 8 (21) . Sulfation of thyroid hormone may serve a special purpose during fetal development, providing protection to tissues that should not be exposed to T3 while allowing 3-dependent tissues to desulfate T3S by expression of sulfatases (22) . How¬ ever, to date, evidence in support of this hypothesis is limited.
The increase in plasma T3S in patients with NTI is explained by a decrease in its clearance either due to an inhibition of ID-I activity or to an inhibition of T3S uptake in tissues expressing this enzyme, i.e. liver and kidneys (23) . The latter may seem unlikely because the liver and kidneys are prominent sites for T3 sulfation. but previous studies in rats suggested that the T3S produced in these tissues is released into the circulation, recaptured and then deiodinated rather than degraded in the same cell in which it is produced (8) . However, it is not excluded that production of T3S is also altered in NTI, and the findings reported by Santini et al. (14) suggest that T3 sulfation may be increased in patients with chronic renal failure (CRF). In (17) . Although active tubular uptake of T3S from blood and subsequent intracellular deiodination is not excluded, the second explanation provided by the authors for the "more than expected" increase in serum T3S in patients with CRF is more appealing.
Santini et al. (14) found that the serum inorganic sulfate concentration was markedly higher in the CRF patients (mean 10.9mmol/l) than in controls (mean 0.3mmol/I), which is known to be due to a decreased renal excretion of this ion in CRF. Previous studies in our laboratory have shown that sulfation of iodo¬ thyronines is impaired in sulfate-depleted cultures of rat hepatocytes (24, 25 (26) . The physiological relevance of such changes in T5 sulfation remains to be explored.
